PDC and neoplasm: Long-term administration of these PHD inhibitors has not demonstrated tumor-initiating or tumor-promoting effects in either animal models or phase III clinical trials, possibly because competitive inhibition of PHD catalytic activity cannot cause permanent and irreversible HIF activation or pharmacological HIF induction is graded and cannot exceed a physiologically acceptable threshold.